Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Role of transforming growth factor-beta signaling in cancer.

de Caestecker MP, Piek E, Roberts AB.

J Natl Cancer Inst. 2000 Sep 6;92(17):1388-402.

PMID:
10974075
2.

Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.

Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE, Roberts AB.

Cancer Res. 2004 Jul 1;64(13):4523-30.

3.

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.

Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M.

Cancer Res. 2004 Aug 1;64(15):5200-11.

4.

Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4.

Saha D, Datta PK, Beauchamp RD.

J Biol Chem. 2001 Aug 3;276(31):29531-7. Epub 2001 May 22.

5.

Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.

Torbenson M, Marinopoulos S, Dang DT, Choti M, Ashfaq R, Maitra A, Boitnott J, Wilentz RE.

Hum Pathol. 2002 Sep;33(9):871-6.

PMID:
12378510
7.

The murine gastrin promoter is synergistically activated by transforming growth factor-beta/Smad and Wnt signaling pathways.

Lei S, Dubeykovskiy A, Chakladar A, Wojtukiewicz L, Wang TC.

J Biol Chem. 2004 Oct 8;279(41):42492-502. Epub 2004 Jul 28.

8.

Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.

Horie K, Yamashita H, Mogi A, Takenoshita S, Miyazono K.

J Cell Physiol. 1998 Jun;175(3):305-13.

PMID:
9572475
9.
10.

Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.

Deacu E, Mori Y, Sato F, Yin J, Olaru A, Sterian A, Xu Y, Wang S, Schulmann K, Berki A, Kan T, Abraham JM, Meltzer SJ.

Cancer Res. 2004 Nov 1;64(21):7690-6.

11.

Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.

Rosendahl A, Speletas M, Leandersson K, Ivars F, Sideras P.

Int Immunol. 2003 Dec;15(12):1401-14.

PMID:
14645149
12.
14.

Intracellular signaling of the TGF-beta superfamily by Smad proteins.

Kawabata M, Imamura T, Inoue H, Hanai J, Nishihara A, Hanyu A, Takase M, Ishidou Y, Udagawa Y, Oeda E, Goto D, Yagi K, Kato M, Miyazono K.

Ann N Y Acad Sci. 1999;886:73-82. Review.

PMID:
10667205
15.

Smad proteins and transforming growth factor-beta signaling.

Schiffer M, von Gersdorff G, Bitzer M, Susztak K, Böttinger EP.

Kidney Int Suppl. 2000 Sep;77:S45-52. Review.

PMID:
10997690
16.

Transforming growth factor-beta and malignant melanoma: molecular mechanisms.

Hussein MR.

J Cutan Pathol. 2005 Jul;32(6):389-95. Review.

PMID:
15953371
17.

Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.

Wang D, Kanuma T, Mizunuma H, Takama F, Ibuki Y, Wake N, Mogi A, Shitara Y, Takenoshita S.

Cancer Res. 2000 Aug 15;60(16):4507-12.

19.

Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells.

Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H, Ungefroren H.

J Biol Chem. 2002 Sep 27;277(39):36118-28. Epub 2002 Jul 24.

20.

Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.

Parekh TV, Gama P, Wen X, Demopoulos R, Munger JS, Carcangiu ML, Reiss M, Gold LI.

Cancer Res. 2002 May 15;62(10):2778-90.

Supplemental Content

Support Center